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Cardiovascular disease is the leading cause of death in the United States.1 It is well established that statins reduce the 
incidence of major coronary events, ischemic stroke, and mor-
tality.2,3 Some of the clinical benefits of statins may be related to 
additional mechanisms other than their lipid-lowering effects.
Our group previously reported that statin use modulates 
the production of aldosterone.4 We demonstrated that among 
individuals with mild to moderate hypertension, statin users 
had 33% lower aldosterone levels.4 Ex vivo studies in rat ad-
renal glomerulosa cells confirmed that statins acutely reduced 
the aldosterone response to adrenal secretagogues.4 These 
findings are significant because renin-angiotensin-aldosterone 
system (RAAS) dysregulation and mineralocorticoid receptor 
activation are involved in the pathogenesis of coronary ar-
tery disease, myocardial infarction, hypertension, atrial fi-
brillation, renal disease, and heart failure.5–7 Furthermore, in 
patients with coronary artery disease, aldosterone levels pre-
dict ischemic events and long-term mortality.8,9
Cav1 (caveolin-1) is critical in cholesterol transport. Cav1, 
a scaffolding protein, is the main component of caveolae and 
is important in transmembrane cholesterol transportation, cho-
lesterol accumulation, and cholesterol efflux.10 Furthermore, 
simvastatin treatment decreased Cav1 expression and increased 
eNOS (endothelial nitric oxide synthase) expression in patients 
who underwent abdominal aortic aneurysm repair.11 The study 
highlighted a potential link between statins and Cav1 and addi-
tionally suggested a possible pleiotropic benefit of statins out-
side of lipid reduction. Statins may exert their effects on eNOS 
through Cav1 as endocytosis of caveolae has been shown to me-
diate the activation of eNOS.10,12 The interplay between Cav1, 
statin use, and aldosterone levels has yet to be determined.
Given that statin use is associated with lower aldosterone 
levels, the primary aim of this study was to evaluate the hypo-
thesis that polymorphisms in Cav1 gene affect the association 
between statin use and aldosterone levels. We hypothesized 
that Cav1 may be important for the uptake of statins by the 
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Abstract—Statin use is associated with lower aldosterone levels. We hypothesized that caveolin-1 may be important for 
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was to test whether the caveolin-1 risk allele (rs926198) would affect aldosterone levels associated with statin use. 
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on both high- and low-sodium diets. A mixed-model repeated-measures analysis was employed with a priori selected 
covariates of age, sex, body mass index, and protocol (low versus high sodium, baseline versus angiotensin II stimulated 
aldosterone). A total of 250 individuals were included in the study; 31 individuals were taking statins (12.4%) and 219 
were not. Among statin users, carrying a caveolin-1 risk allele resulted in a 25% (95% CI, 1–43.2) lower aldosterone level 
(P=0.04). However, among nonstatin users, carrying a caveolin-1 risk allele resulted in no significant effect on aldosterone 
levels (P=0.38). Additionally, the interaction between caveolin-1 risk allele and statin use on aldosterone levels was 
significant (P=0.03). These findings suggest caveolin-1 risk allele carrying individuals are likely to receive the most 
benefit from statin’s aldosterone-lowering properties; however, due to the observational nature of this study, these findings 
need further investigation.  (Hypertension. 2020;76:962-967. DOI: 10.1161/HYPERTENSIONAHA.120.14777.)
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zona glomerulosa in the adrenal cortex and so statin-medi-
ated reductions in aldosterone would be different depend-
ing on Cav1 risk allele status. Specifically, we hypothesized 
that the Cav1 risk allele (rs926198), which is associated with 
decreased levels of Cav1,13 would enhance statin’s ability to 
reduce aldosterone levels. A secondary aim was to investigate 
the relationship between Cav1 risk allele status, statin use, and 
LDL (low-density lipoprotein) levels.
Methods
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.
Hypertensive Pathotype Participants
Participants were studied within the Hypertensive Pathotype 
(HyperPATH) protocol that investigated the pathophysiologic mecha-
nisms and genes involved in hypertension and cardiovascular disease. 
This study consisted of individuals from HyperPATH who were eval-
uated in response to sodium intake and adrenal secretagogues. Five 
percent of participants did not have hypertension, whereas 95% had 
mild to moderate hypertension. All participants were between 18 and 
65 years of age. The protocol included rigorous control of factors 
that influence RAAS, such as body positioning, diurnal variation, and 
sodium intake.
Participants were excluded if they had known or suspected sec-
ondary hypertension—specifically, primary hyperaldosteronism, 
Cushing syndrome, or renovascular hypertension. Participants with 
a history of coronary heart disease, stroke, psychiatric illness, drug 
abuse, renal insufficiency, and uncontrolled hypertension were also 
excluded. Chronic statin use was defined as participants who were on 
a statin for at least 3 months before the study interventions. Anyone 
taking additional or alternative medications other than statins for 
dyslipidemia were excluded. The protocol was approved by the 
Institutional Review Board at each site and informed consent was 
obtained before enrollment. Although other results from HyperPATH 
have previously been reported, the present analyses are original.
HyperPATH Protocol
Details of this protocol have been published previously.14–16 All par-
ticipants completed a standardized protocol across all the study sites 
(Boston, Salt Lake City, and Paris). To control for the influence that 
medications may play in aldosterone secretion, all angiotensin-con-
verting enzyme inhibitors, angiotensin receptor blockers, or mineral-
ocorticoid receptor antagonists were discontinued at least 3 months 
before the start of the study; all other antihypertensive medications 
were discontinued at least 3 weeks before the start of the study.
During the intervention phase, each subject was provided with a 
7-day isocaloric high sodium (HS) diet (200 mEq/day sodium). On 
the sixth day of the HS diet, participants were admitted to the in-
patient research center. After fasting and maintaining an overnight 
supine posture, blood samples were obtained at 8:00 am to meas-
ure aldosterone, cortisol, plasma renin activity, electrolytes, lipid 
profile, and glucose by using standardized and validated methods 
as previously described.14,17 Plasma aldosterone was measured using 
radio-immunoassay (Siemens, Los Angeles, CA) with a sensitivity 
of 0.2 µg/dL and precision of 4% to 6.4%. Blood pressure was meas-
ured at 5-minute intervals using an automated blood pressure device 
(Dinamap, Critikon, Tampa, FL), and the average of 5 consecutive 
readings was used in the analysis. To examine the adrenal response 
of aldosterone to a physiological secretagogue, AngII (angiotensin 
II) infusion was administered at 3 ng/(kg·min) for 60 minutes with 
blood for aldosterone and cortisol repeated at the end of the infu-
sion. After completion of the protocol on HS, subjects were placed 
on a low-sodium (LS) diet (10 mEq/day sodium). On the sixth day of 
the LS diet, participants were again admitted to an inpatient research 
unit, and the same protocol was followed, including measurement of 
baseline hormonal, electrolyte, and lipid profiles as well as adrenal 
steroids after AngII infusion. With each sodium protocol, sodium bal-
ance was confirmed by urinary sodium (HS >150 mEq/24 h and LS 
<30 mEq/24 h). Use of an HS and LS diet permitted the study of 
aldosterone when RAAS was maximally suppressed on HS and max-
imally stimulated on LS.
Cav1 Genotype Selection and Classification
We used rs926198 as the candidate polymorphism of Cav1. This 
single-nucleotide polymorphism was selected based on our group’s 
previous analysis of HapMap variants of the Cav1 gene in the 
HyperPATH dataset.18 If rs926198 was not available, we used the 
Cav1 variant rs917664, which has the same allele frequency and is 
in complete linkage disequilibrium with rs926198 (r2=1). Allele and 
genotype frequencies were in Hardy-Weinberg equilibrium. This var-
iant is associated with insulin resistance, hypertension, and the met-
abolic syndrome.18,19 DNA was genotyped as previously described.19 
Individuals were classified as nonrisk allele carriers if they were ho-
mozygote for the major rs926198 or rs917664 allele and were classi-
fied as risk allele carriers if they had one or two alleles for the minor 
rs926198 or rs917664 allele variant. The selected model represents 
a dominant analysis since we are grouping heterozygous and minor 
allele homozygous as risk allele carriers.
Statistical Analyses
We used an unpaired t test with log transformation for non-normally 
distributed variables for baseline analyses. Binary variables were 
compared using the Fisher exact test. Continuous variables are pre-
sented as mean±SD and categorical variables as a percentage of the 
total sample. Natural log transformation was applied to the outcome 
variables aldosterone and cortisol before analysis. The coefficients 
were exponentiated and interpreted as percentage differences. We 
used a mixed-model repeated-measures analysis with an interaction 
term to evaluate the primary end point of assessing for an interaction 
of Cav1 risk allele carrier status on the association between statin 
use and aldosterone levels. Covariates (fixed effects) were chosen for 
their clinical importance and were age, sex, body mass index, and 
protocol intervention (LS versus high sodium and baseline versus 
AngII stimulated), identical to our prior study4; a random intercept 
was used for the mixed effect. Two-sided P values of <0.05 were con-
sidered statistically significant. All statistical analysis was performed 
using STATA 15.1;StataCorp LLC, College Station, TX.
Results
Characteristics of Participants
Individuals were included if they had Cav1 genotyping and 
statin use was recorded. A total of 250 individuals (80% white) 
were included in the analysis; 31 from participants on statins 
(12.4%) and 219 not on statins. Ninety-nine participants 
were homozygous for the Cav1 nonrisk allele, 123 individu-
als heterozygous, and 33 homozygous for the Cav1 risk allele. 
Participants who were Cav1 risk allele carriers were similar to 
nonrisk allele carriers regarding age, sex, sodium intake, and 
plasma renin activity on HS, and LS diet (Table 1). Of note, sys-
tolic blood pressure was significantly higher in Cav1 risk allele 
carriers in the total population and in nonstatin users. Body 
mass index was higher in the Cav1 risk allele carriers among 
statin users but not in the total population or nonstatin users.
Among the 250 individuals in the HyperPATH cohort, 898 
aldosterone measurements were available. These measure-
ments represent available repeated analyses from 4 differ-
ent intervention points—HS baseline, HS AngII-stimulation, 
LS baseline, and LS AngII-stimulation. There was an av-
erage of 3.6 measurements and at least 2 measurements were 
available for each subject. One-hundred twelve of the 898 
aldosterone measurements (12.4%) were obtained from indi-
viduals with confirmed chronic statin use. Among the statin 
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AngII-stimulation, 28% LS baseline, and 27% LS AngII-
stimulation, and among the nonstatin users, 27% of the mea-
surements were HS baseline, 17% HS AngII-stimulation, 28% 
LS baseline, and 28% LS AngII-stimulation.
Before stratifying by statin use, Cav1 gene status had no 
impact on unadjusted aldosterone levels (P=0.93). However, 
among statin users, individuals who were Cav1 risk allele car-
riers had significantly lower values of aldosterone, 8.4±2.1 
ng/dL, than among Cav1 risk allele carriers, 11.2±2.4 ng/
dl (P=0.02). Of note, among nonstatin users, Cav1 risk 
allele status had no impact on unadjusted aldosterone levels 
(P=0.58). Additionally, Cav1 risk allele status had no signif-
icant effect on cortisol levels either among all participants or 
after stratifying by statin use (Table 1).
Repeated-Measures Analyses by Statin Use and 
Cav1 Carrier Status
In mixed-model repeated-measures ANCOVA after adjust-
ing for age, sex, body mass index, and protocol intervention 
(LS versus HS, baseline versus AngII stimulated), the effect 
of being a Cav1 risk allele carrier in statin users resulted in 
a 25% (95% CI, 1–43.2) lower aldosterone levels (P=0.04; 
Table 2). However, there was no significant effect on aldos-
terone levels of being a Cav1 risk allele carrier in nonstatin 
users (P=0.38). In the model, higher age was associated with 
a lower aldosterone; for every 1-year increase in age, aldoste-
rone was 1.3% (95% CI, 0.7–1.9), lower (P<0.001). As antici-
pated, HS conditions were associated with a 67% (95% CI, 
64.0–69.3) lower aldosterone than LS conditions (P<0.001), 
Table 1. Characteristics of Participants
Measurement












Allele (n=138) P value
Age, y 50±8 50±7 0.87 54±7 54±7 0.66 49±8 49±7 0.95
Female % 41 47 0.42 46 50 0.84 41 46 0.42
BMI, kg/m2 28.2±4.0 29.0±4.2 0.21 28.2±3.2 31.9±4.0 0.03* 28.2±4.1 28.5±4.2 0.61
SBP on HS 143±20 149±20 0.01* 139±22 149±18 0.14 143±20 150±20 0.03*
SBP on LS 129±16 133±18 0.07 126±18 132±13 0.36 129±16 133±18 0.13
Urinary Na on HS, 24 h mmol† 221±61 236±68.2 0.08 211±31.5 254±82.7 0.11 223±63.7 234± 66.4 0.18
Urinary Na on LS, 24 h mmol† 13.7±8.6 15.4±9.2 0.17 14.4±8 17.5±14.2 0.07 14.1±8.5 14.5±7.7 0.58
HS plasma potassium, mmol/L 4.2±0.4 4.1±0.3 0.27 4.0±0.4 4.1±0.3 0.31 4.2±0.3 4.1±0.4 0.48
LS plasma potassium, mmol/L 4.1±0.4 4.2±0.4 0.86 4.1±0.2 4.2±0.4 0.50 4.1±0.3 4.2±0.4 0.25
HS plasma renin activity, ng/
(mL·h)†
0.5±0.5 0.3±0.4 0.73 0.3±0.2 0.4±0.5 0.50 0.5±0.5 0.5±0.5 0.97
LS plasma renin activity, ng/
(mL·h)†
2.4±2.5 1.7±1.1 0.31 1.7±1.2 1.6±1.8 0.40 2.3±1.9 2.5±2.9 0.39
HS LDL cholesterol, mmol/L 124±35 120±47 0.60 108±38 129±53 0.61 124±33 125±37 0.85
Aldosterone, ng/dL (HSb, 
HSstim, LSb, LSstim)†
12.3±2.6 12.4±2.5 0.93 11.2±2.4 8.4±2.1 0.02* 12.5±2.7 13.0±2.5 0.58
Cortisol, µg/dL (HSb, HSstim, 
LSb, LSstim)†
9.7±1.4 9.4±1.5 0.17 10.1±1.4 9.2±1.5 0.21 9.7±1.5 9.4±1.5 0.33
Data reported as mean±SD, except as noted. Comparisons made with unpaired Student t test for continuous variables and Fisher exact for binary variables. AngII 
indicates angiotensin II; BMI, body mass index; Cav1, caveolin-1; HS, high sodium; HSb, HS baseline; HSstim, HS AngII-stimulated; LDL, low-density lipoprotein; LS, low 
sodium; LSb, LS baseline; LSstim, LS AngII-stimulated; and SBP, systolic blood pressure.
*Significant P value (P≤0.05).
†Log transformed t test performed.
Table 2. Adjusted Effects of Cav1 Genotype on the Association Between Statin Use and Aldosterone and Cortisol Levels
Measurement
Total Study Population Statin Users Nonstatin Users
Cav1 Risk Allele Effect, 
% [95% CI] P Value
Cav1 Risk Allele Effect, % 
[95% CI] P Value
Cav1 Risk Allele Effect, 
% [95% CI] P Value
Aldosterone, ng/dL (HSb, HSstim, 
LSb, LSstim)
0.6% [−8.8 to 10.8] 0.91 −25% [−1.0 to −43.2] 0.04* 4.6% [−4.1 to 13.9] 0.34
Cortisol, µg/dL (HSb, HSstim, LSb, 
LSstim)
−2.0% [−9.4 to 6.1] 0.63 −9.6% [−26.3 to 10.8] 0.42 0.7% [−7.4 to 10.0] 0.87
Cav1 indicates caveolin-1; HSb, HS baseline; HSstim, HS AngII-stimulated; LDL, low-density lipoprotein; LS, low sodium; LSb, LS baseline; and LSstim, LS AngII-
stimulated.
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and AngII-stimulated aldosterone levels were 158% (95% CI, 
143–172) higher than baseline levels (P<0.001). Sex and body 
mass index did not significantly contribute to the model. In 
comparison, there was no difference in aldosterone levels by 
Cav1 genotype among nonstatin users (P=0.38). Again, in the 
adjusted model, cortisol levels were unaffected by Cav1 gen-
otype status.
Cav1 Genotype Interacts With the Association 
Between Statin Use and Aldosterone
We then examined the interaction between Cav1 genotype and 
statin use in repeated-measures analysis using all 4 measure-
ments of aldosterone while adjusting for potential confound-
ers. Cav1 genotype showed a significant interaction with statin 
use (P=0.029) (Figure). Age, dietary sodium, and baseline 
versus AngII stimulation remained important in the model.
Cav1 Genotype Does Not Interact With the 
Association Between Statin Use and LDL
We next examined the effect of the interaction between Cav1 
genotype and statin use on LDL levels. We had a maximum 
of 2 LDL measurements for each individual (average of 1.7), 
1 measured under LS conditions and 1 measured under HS 
conditions. Using both measurements of LDL while adjusting 
for potential confounders, Cav1 risk allele status had no sig-
nificant interaction (P=0.37).
Discussion
We demonstrated that in hypertensive participants the Cav1 
risk allele, rs926198, modulates the association of statin use 
with aldosterone. Among statin users, Cav1 risk allele carri-
ers had a 25% (95% CI, 1–43.2) lower aldosterone level than 
Cav1 nonrisk allele carriers. However, among nonstatin users, 
there was no significant difference in aldosterone levels by 
Cav1 genotype, so this is a statin-specific effect. The differ-
ence in the Cav1 effect in statin users versus nonstatin users 
showed a significant interaction. These findings suggest that 
Cav1 risk allele carriers will derive the most aldosterone-low-
ering benefit of statins. This effect appeared to be specific to 
the adrenal gland as there was no effect on lipids and was also 
specific to aldosterone, as cortisol levels were not modified by 
Cav1 risk allele status.
Our assessments of aldosterone were conducted under 
conditions whereby the key secretagogues of aldosterone 
were controlled to permit an isolated investigation of other 
influences on aldosterone secretion. Specifically, this study 
controlled for multiple factors that can affect aldosterone se-
cretion including physical activity, posture, dietary sodium in-
take, sleep-wake cycles, food intake, and time of day. Through 
these techniques, we minimize the potential noise in assessing 
aldosterone production.
Our findings raise several important clinical questions. 
Even a moderate decrease in aldosterone is likely clinically 
relevant. Aldosterone is a well-known key regulator of sodium 
and potassium balance, blood pressure, endothelial function, 
renal disease, and cardiovascular remodeling. Aldosterone 
blockers improve survival in heart failure and in patients with 
myocardial infarction. Thus, statins may have added benefit in 
individuals with the Cav1 risk allele. Because statins reduce 
aldosterone levels in Cav1 risk allele carriers, these individu-
als may be more likely to show a decrease in blood pressure 
with initiation of statin therapy. However, clinicians may want 
to avoid the aldosterone effect in patients prone to hyperkale-
mia or in those with already low blood pressure or orthostatic 
intolerance. Perhaps statins may also be useful as an adjuvant 
treatment for hyperaldosteronism.
As this is an observational study, we must consider con-
founding factors, for example, blood pressure, as explanations 
for our findings. Therefore, future prospective studies are nec-
essary to assess the role of Cav1 in statins’ aldosterone-low-
ering effects. However, assuming this association proves to 
be true, it is interesting to consider potential mechanisms by 
which Cav1 may influence aldosterone levels in statin users but 
not nonstatin users. We have previously shown that plasma al-
dosterone levels are not different between wild-type and Cav1 
knockout mice (Cav1−/−).20 In our current study, importantly, 
the renin and potassium levels were not affected by Cav1 
risk allele status in either statin or nonstatin users (Table 1). 
Additionally, ACTH (corticotropin) levels are unlikely to be 
different as cortisol levels were similar, suggestive that classi-
cal regulatory factors are not impacted by Cav1. Interestingly, 
in a meta-analysis, statins were associated with decreased tes-
tosterone levels in both men and women, raising the possibility 
that statins may affect production of steroids other than aldos-
terone.21 It is thought simvastatin inhibits the later steps of tes-
ticular steroidogenesis.22 Our finding that statin use does not 
affect cortisol levels is consistent with previous findings in a 
randomized, placebo-controlled study of 12 weeks of simvas-
tatin 80 mg/day that did not demonstrate changes in basal cor-
tisol levels or cortisol response to a 6-hour ACTH infusion.23
Cav1 is essential for creating caveolae, 60 to 80 nm invagi-
nations in the cell membrane in which multiple receptors are 
located.24 Caveolae form membrane domains at the plasma 
membrane, serve as carriers in endocytosis, and can facili-
tate direct signaling at the membrane.25 Caveolin-1 plays an 
important role in aldosterone signaling26 and has been iden-
tified in adrenocortical cells. In humans, Cav1 minor allele 
homozygotes had the lowest levels of Cav1 expression.13,24 
Figure. Adjusted aldosterone values in nonstatin/statin users and Cav1 
(caveolin-1) nonrisk/risk allele carriers. Among statin users, Cav1 risk allele 
carriers had a 25% lower aldosterone (P=0.04). Among nonstatin users, 
there was no effect of the Cav1 risk allele on aldosterone levels (P=0.38). 
The interaction between Cav1 allele and statin use was significant 
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Cav1 minor allele carriers have increased insulin resistance, 
a higher 10-year Framingham score, and higher prevalence 
of diabetes, dyslipidemia, and the metabolic syndrome.19 Yet, 
Cav1 knockout mice have decreases in atherosclerosis—an 
effect specific to endothelial caveolin.12
How Cav1 risk allele carriers modify aldosterone levels 
is uncertain. It is possible that Cav1, in its structural role in 
caveolae, functions as a gatekeeper and inhibits statins’ ability 
to enter or enhances its ability to exit the zona glomerulosa. 
Thus, Cav1 risk allele carriers, presumably reflective of a 
reduction in Cav1 levels, more easily allow statin uptake or 
reduce its exit from the zona glomerulosa cell. If a statin’s 
effect on aldosterone secretion is directly related to its resident 
time in the cell, then either of these scenarios would explain 
why Cav1 risk allele carriers have lower aldosterone levels on 
statins than nonrisk allele carriers. Another potential mech-
anism is that some statins may influence Cav1 production or 
function. Thus, certain, but not all, statins could amplify the 
effect of lower Cav1 expression in Cav1 risk allele carriers 
as discussed earlier. That statins may have such an effect is 
suggested by a study with rosuvastatin. This statin decreased 
Cav1 expression in apoE−/−, dyslipidemic mice in vivo.27
The liver, which has one of the lowest relative expressions 
of Cav1 protein, is the main source of endogenous lipid pro-
duction and the primary site of statins’ actions.28 Uptake of 
both lipophilic and hydrophilic statins involves passive diffu-
sion through hepatocyte cell membranes as well as an ATP-
dependent carrier-mediated active transport.28,29 Our findings 
showed no significant difference in LDL level by Cav1 geno-
type, although preclinical studies have shown that Cav1 may 
be involved in the regulation of lipoprotein metabolism and 
transcytosis of LDL.30,31 Future prospective randomized con-
trolled studies are needed to assess the impact of Cav1 geno-
type on the effectiveness of statins in lowering LDL.
Our study has some limitations. The sample size was small, 
and in this observational study, statin intervention was not ran-
domized. Thus, unmeasured confounding variables associated 
with statin users cannot be ruled out. It should be pointed out 
that systolic blood pressure was higher in Cav1 risk allele 
carriers, which may lead to confounding. The observational 
design prevented us from evaluating a causal relationship be-
tween Cav1, statin use, and aldosterone levels. Additionally, 
there was a relatively small number of statin users (n=31), of 
which only 18 individuals carried the Cav1 risk allele, which 
may have limited our ability to detect additional differences 
between Cav1 risk allele carriers and nonrisk allele carriers. 
For example, the 9.6% lower cortisol levels among Cav1 risk 
allele carriers may or may not reach significance if the sample 
size were larger and will need further studies. If our observa-
tions are confirmed in future prospective studies, the specific 
mechanism for the Cav1 risk allele in lowering aldosterone in 
chronic statin users needs elucidation. We did not have suffi-
cient power to determine whether the statin effect varied with 
the type of statin—lipophilic or hydrophilic—nor whether the 
number of Cav1 risk alleles impacts aldosterone reduction. 
Our observational results should be validated in prospective 
randomized studies with controlled RAAS modulators as well 
as in isolated zona glomerulosa cells from Cav1−/− and wild-
type mice.
Perspectives
In summary, after controlling for factors that influence the 
RAAS, we have shown that Cav1 risk allele carrier status 
affects the association between statin use and aldosterone lev-
els. Cav1 risk allele carrying individuals are likely to receive 
the most benefit from the aldosterone-lowering properties of 
statins; even a modest decrease in aldosterone is likely clini-
cally relevant. Prospective studies are needed to confirm these 
observational findings and may provide a basis for clinical 
stratification based on Cav1 risk allele carrier status.
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What Is New?
•	Among statin users, being a carrier for the caveolin-1 risk allele 
(rs926198) was associated with a 25% lower aldosterone level as com-
pared to those who are homozygous for the nonrisk allele.
•	Among nonstatin users, aldosterone levels were similar between carriers 
and noncarriers of the caveolin-1 risk allele.
What is Relevant?
•	Caveolin-1 risk allele carrying individuals are likely to receive the most 
benefit from statin’s aldosterone-lowering properties; even a moderate 
decrease of aldosterone is likely clinically relevant.
Summary
This cross-sectional study among 250 hypertensive individuals 
determined whether caveolin-1 (rs926198) genotype impacts the 
association between statin use and lower aldosterone levels. We 
demonstrated that among statin users, caveolin-1 risk allele car-
riers (≈60% of the study population) had a 25% lower aldosterone 
level than caveolin-1 nonrisk allele carriers. These findings suggest 
that caveolin-1 risk allele carriers will derive the most aldosterone-
lowering benefit of statins; however, as this is a small observational 
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